Performance of RGNX Regenxbio | -36.6% in 12m
Compare RGNX with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Regenxbio with its related Sector/Index XBI
Performance Duell RGNX vs XBI
| TimeFrame | RGNX | XBI |
|---|---|---|
| 1 Week | -9.40% | -3.57% |
| 1 Month | -16.5% | -2.54% |
| 3 Months | -27.9% | -3.08% |
| 6 Months | -38.7% | 14.30% |
| 12 Months | -36.6% | 46.30% |
| YTD | -46.9% | 7.29% |
| Rel. Perf. 1m | -1.34 | |
| Rel. Perf. 3m | -3.85 | |
| Rel. Perf. 6m | -6.28 | |
| Rel. Perf. 12m | -7.28 | |
| Spearman 1m | -0.12 | 0.261 |
| Spearman 3m | -0.80 | 0.027 |
Is Regenxbio a good stock to buy?
No, based on ValueRay Fundamental Analyses, Regenxbio (NASDAQ:RGNX) is currently (October 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -57.61 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RGNX as of October 2024 is 6.79. This means that RGNX is currently overvalued and has a potential downside of -30.29% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RGNX as of October 2024 is 6.79. This means that RGNX is currently overvalued and has a potential downside of -30.29% (Sold with Premium).
Is RGNX a buy, sell or hold?
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: RGNX is performing better - Values below 0%: RGNX is underperforming
Compare RGNX with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -8.66% | -18.00% | -53.77% | -78.55% |
| US NASDAQ 100 | QQQ | -8.88% | -17.64% | -53.97% | -79.63% |
| US Dow Jones Industrial 30 | DIA | -8.14% | -17.54% | -50.09% | -68.55% |
| German DAX 40 | DAX | -8.26% | -15.92% | -45.38% | -69.86% |
| UK FTSE 100 | ISFU | -8.08% | -13.61% | -47.36% | -60.84% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -12.10% | -36.81% | -54.45% | -52.61% |
| Hongkong Hang Seng | HSI | -8.02% | -21.86% | -58.19% | -48.59% |
| India NIFTY 50 | INDA | -6.61% | -10.29% | -45.37% | -66.34% |
| Brasil Bovespa | EWZ | -7.85% | -13.16% | -31.60% | -34.81% |
RGNX Regenxbio vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -8.65% | -18.21% | -51.16% | -80.73% |
| Consumer Discretionary | XLY | -6.96% | -14.22% | -51.69% | -68.71% |
| Consumer Staples | XLP | -8.70% | -15.05% | -48.75% | -61.22% |
| Energy | XLE | -8.96% | -17.31% | -33.70% | -43.69% |
| Financial | XLF | -8.62% | -20.22% | -54.15% | -86.04% |
| Health Care | XLV | -7.52% | -13.95% | -46.00% | -58.52% |
| Industrial | XLI | -7.57% | -18.83% | -50.56% | -79.20% |
| Materials | XLB | -8.00% | -17.87% | -48.18% | -66.77% |
| Real Estate | XLRE | -8.51% | -15.34% | -62.26% | -76.11% |
| Technology | XLK | -8.98% | -19.39% | -55.03% | -80.21% |
| Utilities | XLU | -9.29% | -18.77% | -64.37% | -78.25% |
| Aerospace & Defense | XAR | -7.51% | -18.69% | -57.52% | -77.87% |
| Biotech | XBI | -5.83% | -14.00% | -53.04% | -82.85% |
| Homebuilder | XHB | -3.52% | -12.10% | -52.78% | -106.04% |
| Retail | XRT | -5.93% | -15.51% | -43.11% | -67.50% |
Does Regenxbio outperform its market, is RGNX a Sector Leader?
No, over the last 12 months Regenxbio (RGNX) made -36.55%, while its related Sector, the SPDR S&P Biotech (XBI) made 46.30%.
Over the last 3 months RGNX made -27.85%, while XBI made -3.08%.
No, over the last 12 months Regenxbio (RGNX) made -36.55%, while its related Sector, the SPDR S&P Biotech (XBI) made 46.30%.
Over the last 3 months RGNX made -27.85%, while XBI made -3.08%.
| Period | RGNX | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | -16.54% | -2.54% | 1.46% |
| 3 Months | -27.85% | -3.08% | 4.69% |
| 12 Months | -36.55% | 46.30% | 42.00% |